Research Progress in Neurodegenerative Diseases

Dear Colleagues,

Neurodegenerative diseases represent a large group of neurological disorders with heterogeneous clinical and pathological expressions, affecting specific groups of neurons, as well as specific brain areas. Several environmental and genetic factors are associated with neurodegenerative diseases, and aging has been found to be an important risk factor. The fine-tuning of the progressive loss of neurons drives nervous system dysfunction via the formation of specific neuropathological changes in the brain, including cellular inclusions, extracellular protein deposits, and the reshaping of cell morphology and neural networks. Many different forms of neurodegenerative diseases are recognized, such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis, multiple sclerosis, prion diseases, spongiform encephalopathies, spinocerebellar ataxias, and others. However, as recently evidenced with the neurological consequences observed in patients with COVID-19, a new disease called NeuroCOVID-19 has emerged, and it might constitute a new frontier of research. We are pleased to invite you to make a submission to this Special Issue, titled “Research progress in Neurodegenerative Diseases”.

It has a multidisciplinary emphasis on the interplay between vascular pathology, neuroinflammation, and the progression of neurodegenerative diseases—related to neurobiology and clinical studies.

This Special Issue aims to better understand all aspects of neurodegenerative diseases while also considering clinical and preclinical neuroimaging and biomarker studies, molecular and cell biology, as well as pharmacology, the microbiota gut–brain axis, and therapeutic insights, such as RNA therapy.

We accept high-quality papers in the form of brief reports, research articles, and review articles from a broad spectrum of scientific research areas, ranging from neurobiology and neuroscience to neuro-molecular medicine. All studies in neurodegenerative disease represent the exploration of a new frontier of biomedicine and the potential development of new diagnostic tests and therapies for neurodegenerative diseases.

Dr. Christian Barbato
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• neurodegenerative diseases
• neurobiology
• Alzheimer's disease
• Parkinson's disease
• prion diseases
• amyotrophic lateral sclerosis
• NeuroCOVID-19
• neuroimaging
• microbiota gut-brain axis
• RNA therapy